CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
The IND234 clinical trial, conducted by the Canadian Cancer Trials Group (CCTG), uses liquid biopsy technology to screen for genomic markers in prostate cancer patients.
After the liquid biopsy analysis, patients with specific DNA markers are assigned to one of five new therapies targeted at their unique form of prostate cancer. Researchers want to see if the markers identified in the screening process can help predict which patients will be helped the most by the targeted treatments.
Citations for two previously published CCTG trials are now available online.
The New England Journal of Medicine Notable Articles of 2018 recognizes the significance of the TAYLORx | CCTG MAC12 study, in addition, the Journal of Clinical Oncology has also named TAILORx as one of the most important clinical research advances of 2018.
CCTG is pleased to announce that the CRC7 has met its accrual goal of 1180 patients and has been closed to accrual. CCTG CRC.7 (N1048) trial: A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision (PROSPECT)
Effective April 15, 2019, participants at our member sites will be required to attest to completion of this one-time training requirement prior to becoming active on a trial Participants List.
Ibrutinib, the first in class Bruton’s tyrosine kinase inhibitor is the first targeted therapy approved in chronic lymphocytic leukemia (CLL) and quickly became the standard of care treatment for relapsed and refractory CLL based on its demonstrated efficacy and safety. Prior to this trial Ibrutinib had not been compared against a standard of care chemo-immunotherapy.
These CCTG trials have been formally permanently closed/terminated. No further ethics approvals or folow up data are required, more information can be found on the CCTG website under the "Toolbox".
